Integrating Supervised Consumption into a Continuum of Care for People Who Use Drugs
The opioid overdose crisis in North America demonstrates a need to scale up supervised-consumption services, as well as to experiment with a mix of potential service models. A range of new-to-Canada models have been implemented over the past two years. With an increasing diversity of models of supervised- consumption services in operation, there exists a window of opportunity for a second generation of research in this area that moves from asking whether such services are effective in reducing drug-related harms – which we know them to be – to asking whether, how, and under what conditions their benefits can be maximized.
View the full article.
Related Content
Integrated Supervised Injection Services Evaluation in Toronto, Ontario
The CDPE is leading a study to evaluate the impact of integrating supervised injection services within community healthcare agencies in Toronto, Ontario.
View
COVID-19 Rapid Assessment
The CDPE is leading a rapid assessment of the COVID-19 pandemic’s impact on people who inject drugs in Toronto.
View
Safer Opioid Supply Programs Evaluation in Toronto, Ontario
The CDPE is leading a study to evaluate the impact of safer opioid supply programs in Toronto, Ontario.
ViewRequiring help injecting among people who inject drugs in Toronto, Canada: Characterising the need to address sociodemographic disparities and substance-use specific patterns
As supervised consumption services (SCS) are scaled-up across Canada, information on those who require help injecting is necessary to inform equitable service uptake. We characterised the sociodemographic, structural and drug use correlates of needing help injecting among a cohort of people who inject drugs in Toronto, Canada.
View
Validation of Self-reported Opioid Agonist Treatment Among People Who Inject Drugs Using Prescription Dispensation Records
Studies of people who inject drugs (PWID) commonly use questionnaires to determine whether participants are currently, or have recently been, on opioid agonist treatment for opioid use disorder. However, these previously unvalidated self-reported treatment measures may be susceptible to inaccurate reporting.
View
Evaluating interventions to facilitate opioid agonist treatment access among people who inject drugs in Toronto, Ontario during COVID-19 pandemic restrictions
In March 2020, following a provincial COVID-19 emergency declaration, modifications to opioid agonist treatment (OAT) were introduced in Ontario, Canada to promote treatment access amid the pandemic and ongoing opioid overdose crisis. Our objectives were to evaluate the effects of these modifications on OAT enrollment and on receipt of take-home doses and the frequency of urine drug screening among OAT-enrolled participants, as well as to investigate concurrent pre- and post-implementation trends in opioid-related overdoses and all-cause mortality.
View
The Ontario Integrated Supervised Injection Services Cohort Study of People Who Inject Drugs in Toronto, Canada (OiSIS-Toronto): Cohort Profile
The Ontario Integrated Supervised Injection Services cohort in Toronto, Canada (OiSIS-Toronto) is an open prospective cohort of people who inject drugs established to evaluate the impacts of supervised consumption services integrated within three community health agencies on health status and service use.
View
Supervised Consumption Service Use and Recent Non-Fatal Overdose among People Who Inject Drugs in Toronto, Canada
This study examined associations between SCS use and non-fatal overdose among PWID in Toronto, Ontario, Canada amidst the current opioid overdose epidemic, drawing on baseline data from a cohort of PWID including individuals who do and do not use SCS.
View